CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...
Phase 3
Jacksonville, Florida, United States and 37 other locations
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia...
Phase 4
Jacksonville, Florida, United States and 50 other locations
with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 3
Jacksonville, Florida, United States and 16 other locations
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; par...
Phase 3
Saint Augustine, Florida, United States and 151 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Jacksonville, Florida, United States and 130 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Jacksonville, Florida, United States and 82 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 3
Jacksonville, Florida, United States and 69 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Saint Augustine, Florida, United States and 179 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have...
Phase 3
Jacksonville, Florida, United States and 231 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...
Phase 1, Phase 2
Jacksonville, Florida, United States and 55 other locations
Clinical trials
Research sites
Resources
Legal